New Vice President for Bioanalytical Development lab appointed by Cytovance Biologics

Cytovance^® Biologics LLC, a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from mammalian cell culture, today announced the addition of Dr. Jeffrey Su as Vice President of Bioanalytical Development to its diverse and growing scientific staff. Dr. Su will head up the state of the art Bioanalytical Development laboratory supporting existing and new client needs. This lab is part of the ongoing strategic expansion of the facilities to add scientific capabilities and the 1,000L Microbial, 1,000L and 5,000L Mammalian process train capacity. “I see this addition as a key placement to meet the needs of our expansion,” said Darren Head, President & CEO of Cytovance^® Biologics.

The Bioanalytical Development lab will be housed in Cytovance’s multi-product cGMP production facility in Oklahoma City. The 44,000 sq. ft. facility meets the latest international regulatory standards and is custom-designed for efficient and cost-effective production. Cytovance specializes in the execution of clinical production of antibody and recombinant protein products derived from cell culture at scales up to 500L (w/v) from both fed-batch and perfusion processes.